Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20259608 | 0.80 | OPRM1 (0.48) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL348556 | 0.78 | OPRM1 (0.53) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL28309448 | 0.77 | OPRM1 (0.42) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| Lithium Ion SCHEMBL27694899 | 0.76 | OPRM1 (0.51) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL23225662 | 0.75 | OPRM1 (0.79) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL19295066 | 0.75 | KCNN4 (0.38) | SLC6A4 | |
| SCHEMBL349662 | 0.75 | OPRM1 (0.53) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL17596349 | 0.75 | JAK2 (0.49) | — | |
| SCHEMBL17595785 | 0.73 | ALDH1A1 (0.43) | — | |
| SCHEMBL343558 | 0.73 | OPRM1 (0.67) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-RE49687-E1 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-10 | — | — | US | disclosed |
| US-10246464-B2 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-04-02 | — | — | US | disclosed |
| WO-2018106818-A1 | METHODS OF PROMOTING BETA CELL PROLIFERATION | KURA ONCOLOGY, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | WELLSPRING BIOSCIENCES LLC | 2017-08-31 | — | — | US | disclosed |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | WELLSPRING BIOSCIENCES LLC | 2017-08-31 | — | — | US | disclosed |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | WELLSPRING BIOSCIENCES LLC | 2017-08-31 | — | — | US | disclosed |
| WO-2016040330-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246464-B2 | Thienopyrimidine and thienopyridine compounds and methods of use thereof | MLLT1, MEN1, TERF2IP | OPRM1 4782/4885OPRD1 4814/4885OPRK1 4802/4885 |
| US-20170247391-A1 | THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MEN1, TERF2IP | OPRM1 4782/4885OPRD1 4814/4885OPRK1 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.